With 0.66 million shares changed hands, the volume of the stock remained lighter than its average volume of 0.67 million shares. The 52-week range on ZYME shows that it touched its highest point at $17.70 and its lowest point at $8.21 during that stretch. It currently has a 1-year price target of $21.56. Beta for the stock currently stands at 1.23.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of ZYME was down-trending over the past week, with a drop of -12.77%, but this was up by 13.05% over a month. Three-month performance dropped to -20.83% while six-month performance fell -22.89%. The stock gained 23.96% in the past year, while it has lost -22.78% so far this year. A look at the trailing 12-month EPS for ZYME yields -1.50 with Next year EPS estimates of -0.91. For the next quarter, that number is -0.50. This implies an EPS growth rate of -0.13% for this year and 44.02% for next year. EPS is expected to decline by -0.86% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 15.81%.
Float and Shares Shorts:
At present, 69.58 million ZYME shares are outstanding with a float of 67.40 million shares on hand for trading.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for ZYME since 4 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 1 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$1.29776 being high and -$1.80597 being low. For ZYME, this leads to a yearly average estimate of -$1.44296. Based on analyst estimates, the high estimate for the next quarter is -$0.06 and the low estimate is -$0.51. The average estimate for the next quarter is thus -$0.36.
